High Blood Pressure & Cardiovascular Prevention最新文献

{"title":"Reciprocal Relationship Between Cardiovascular Risk and Attainment of Blood Pressure and Cholesterol Targets in Users of a Mobile Health App.","authors":"Fabian Starnecker, Johannes Krefting, Leon Nissen, Marius Schwab, Marko Jovanovic, Sinann Al Najem, Moritz von Scheidt, Stephan Jonas, Heribert Schunkert, Lara Marie Reimer","doi":"10.1007/s40292-026-00806-4","DOIUrl":"https://doi.org/10.1007/s40292-026-00806-4","url":null,"abstract":"<p><strong>Introduction: </strong>Voluntary users of mobile health (mHealth) apps indicate an interest in lowering cardiovascular disease (CVD) risk. It is unclear by which extent blood pressure (BP) or cholesterol treatment targets are achieved in such individuals.</p><p><strong>Aim: </strong>This study aimed to evaluate the attainment of guideline-recommended BP and cholesterol targets across different CVD risk categories among mHealth app users.</p><p><strong>Methods: </strong>We grouped users of the publicly available German mHealth app HerzFit, who donated their data for scientific evaluations, into individuals with \"low-to-moderate risk\", \"high risk\" and \"very high risk\" of future CVD events. Risk factor control was assessed according to presence of antihypertensive or cholesterol-lowering treatment and achievement of guideline-recommended BP and cholesterol treatment targets.</p><p><strong>Results: </strong>Individual data sets from 1,230 HerzFit users without CVD who provided BP and cholesterol levels were used for the analysis. 471 users were categorized as low (-to-moderate) risk (38.3%), 595 as high risk (48.4%), and 164 as very high risk (13.3%). Antihypertensive treatment was reported in 36.9% of low-risk individuals, 58.2% of high-risk individuals (p<0.001 vs. low), and 59.1% of very high-risk individuals (p<0.001 vs. low). Cholesterol-lowering therapy was present in 29.3%, 41.7% (p<0.001 vs. low), and 40.9% (p=0.01 vs. low), respectively. Use of high-intensity statins (9%) and statin-ezetimibe combinations (5%) was low across all risk groups. BP control was achieved in 79.0% of low-risk individuals, 65.4% of high-risk individuals (P<0.001 vs. low) and 48.2% of very high-risk individuals (p<0.001 vs. low). Respective numbers for cholesterol control were 30.4%, 12.8% (p<0.001 vs. low) and 11.0% (p<0.001 vs. low).</p><p><strong>Conclusions: </strong>Despite being treated more frequently, individuals at high or very-high risk achieved poorer BP and cholesterol control compared to individuals at low-to-moderate risk. Thus, effective medications are particularly underutilized in individuals at high risk for future CVD events, despite an expressed interest in management of cardiovascular health.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of Risk Perception Cut-Offs in Italian Brief PRHDS (PRHDS-BI): Implications for Primary Cardiovascular Prevention.","authors":"Rosa Debora, Adorni Roberta, Trenta Alessia, D'Andrea Miriana, Alberti Mariangela, Gianfranceschi Enrico, Di Matteo Roberta, Steca Patrizia, Maconi Antonio, Manara Duilio Fiorenzo, Faini Andrea, Simonelli Niccolò","doi":"10.1007/s40292-026-00793-6","DOIUrl":"10.1007/s40292-026-00793-6","url":null,"abstract":"<p><strong>Introduction: </strong>Effective cardiovascular (CV) prevention requires accurate risk estimation and patient engagement, which depends on perceived risk. The Perception of Risk of Heart Disease Scale (PRHDS) is a validated tool, yet clinical thresholds for its brief Italian version are lacking.</p><p><strong>Aim: </strong>To provide further validation of the Brief Italian version of the PRHDS (PRHDS-BI) in a new cohort, examining convergent and divergent validity, and to establish clinical thresholds and a discrepancy index comparing perceived risk with objective estimates.</p><p><strong>Methods: </strong>285 adults (40-69 years) were involved in this multicentre cross-sectional study (NCT06190743). Participants were without a history of CV disease and completed the PRHDS-BI and the Patient Health Questionnaire-4 (PHQ-4). CV real risk was estimated using the Systematic Coronary Risk Evaluation 2 (SCORE2). Confirmatory Factor Analysis (CFA), correlation analyses, and cut-off definitions were used to validate the scale and analyze risk discrepancies.</p><p><strong>Results: </strong>The PRHDS-BI showed good internal consistency and strong convergent validity. Clinical thresholds were defined by percentiles: scores 6-12 (low/moderate), 13-17 (high), and 18-24 (very high). A significant mismatch emerged: 63.5% of participants at low/moderate actual risk overestimated their risk, while 80% at very high actual risk underestimated it. This perception-reality gap was statistically confirmed.</p><p><strong>Conclusions: </strong>The PRHDS-BI is a valid tool for assessing CV risk perception. Establishing thresholds allows for tailored risk communication and patient-centered interventions, particularly by nursing professionals in primary prevention settings.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"307-316"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on Office Blood Pressure Measurement in Daily Practice in the Hypertension Centers of the Italian Society of Hypertension.","authors":"Francesca Saladini, Fabiolucio Albini, Antonino Di Guardo, Gian Paolo Fra, Lucio Mos, Stefano Omboni, Pasquale Predotti, Franco Rabbia, Giuliano Tocci, Gianfranco Parati, Paolo Palatini, Maria Lorenza Muiesan, Agostino Virdis, Grzegorz Bilo","doi":"10.1007/s40292-025-00778-x","DOIUrl":"10.1007/s40292-025-00778-x","url":null,"abstract":"<p><strong>Introduction: </strong>Office blood pressure (BP) measurement is the cornerstone for the diagnosis of arterial hypertension.</p><p><strong>Aim: </strong>To investigate how office BP is measured in clinical practice among the hypertension centers of the Italian Society of Hypertension in comparison to what is recommend by the latest guidelines.</p><p><strong>Methods: </strong>Coordinators of hypertension centers affiliated to the Italian Society of Hypertension were invited by email to complete an online survey including 26 questions regarding the equipment (devices and cuffs) available in the centers, office BP measurement procedure and possible additional measures performed by the devices.</p><p><strong>Results: </strong>We obtained answers from 72 of the 119 centers (response rate 60.5%). The majority of the responders were older than 55 years (55.5%) and were from the North of Italy (61.1%). 95.6% stated the use of a validated device: 65.3% used automatic oscillometric devices, 27.8% an aneroid device, while 6.9% a manual device with a digital column. Unattended BP measurements were performed in 1.4% of the cases. Normal size cuff was available among 97.2% and large cuff among 83.1% of the centers. The majority tested BP in two different positions supine or sitting and standing positions, but there was a quarter of centers that measured BP only in one position. 38% of the responders performed three BP recordings, 38% at least two, but 5.7% measured BP only once. 42.3% of the devices used were able to detect atrial fibrillation.</p><p><strong>Conclusion: </strong>Our survey depicted a considerable heterogeneity of office BP measurement methodology in daily practice, not always aligned with current guidelines.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"297-305"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Functional Reserve and Its Association with eGFR Trajectories and Blood Pressure Patterns in Hypertensives with Preserved Renal Function.","authors":"Aikaterini Damianaki, Kyriakos Dimitriadis, Emelina Stambolliu, Panagiotis Iliakis, Dimitrios Konstantinidis, Konstantinos Tsioufis, Dimitrios Petras","doi":"10.1007/s40292-026-00782-9","DOIUrl":"10.1007/s40292-026-00782-9","url":null,"abstract":"<p><strong>Introduction: </strong>Renal Functional Reserve (RFR) is a promising marker for detecting early nephron loss and functional renal mass.</p><p><strong>Aim: </strong>We evaluated the relationship between RFR and changes in eGFR over time in hypertensive (HT) and normotensive (NT) individuals.</p><p><strong>Methods: </strong>In this 24-month prospective study, newly diagnosed essential HT and NT individuals with eGFR ≥60 ml/min/1.73m² were included. At baseline, RFR was measured by endogenous creatinine clearance after an oral protein load in both groups, alongside 24-hour ambulatory blood pressure (BP) profile in HT. Serum creatinine was reassessed at months 12 and 24.</p><p><strong>Results: </strong>A total of 51 HT and 20 NT subjects (mean age 53.2 ± 12.1 and 54.3 ± 10.0 years) completed the study. RFR levels did not differ between groups (25.1 ± 18.7 vs. 27.7 ± 15.7 ml/min, p = 0.6). No significant difference was found in the annual and the two-year eGFR change between HT and NT. At 24 months, HT and NT with RFR ≥30 ml/min showed less pronounced declines in eGFR compared to those with RFR <30 ml/min (0.5 ± 2.6 vs. - 1.4 ± 1.7 ml/min/1.73m², p =0.002 and - 0.6±1.3 vs. - 1.6 ± 0.7 ml/min/1.73m², p = 0.02 respectively). HT with high RFR were more frequently dippers (64.4% vs. 34.4%, p < 0.05).</p><p><strong>Conclusions: </strong>RFR does not differ between HT and NT with preserved renal function but normal RFR is associated with slower eGFR decline. Reduced RFR correlates with non-dipping BP in HT.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"317-326"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of regional and whole body sympathetic normalization during antihypertensive drug treatment: a potential link for the residual risk.","authors":"Guido Grassi, Rita Facchetti, Ana Jelakovic, Cesare Cuspidi","doi":"10.1007/s40292-026-00786-5","DOIUrl":"10.1007/s40292-026-00786-5","url":null,"abstract":"<p><strong>Introduction: </strong>It is unknown whether the failure of antihypertensive drug treatment to normalize sympathetic cardiovascular (CV) function reported in previous studies selectively affects regional sympathetic CV outflow or it also involves whole body neuroadrenergic drive.</p><p><strong>Aim: </strong>The present study examines the impact of antihypertensive drug treatment on regional and whole body sympathetic CV influences.</p><p><strong>Methods: </strong>Fifthyfour essential hypertensive patients were included in the study. In each patient measurements consisted of the microneurographic recording of muscle sympathetic nerve traffic (MSNA) and the assay of venous plasma norepinephrine (NE). They were performed before and during an antihypertensive drug treatment (monotherapy or two-drugs combination) prolonged for a 3 months period. Measurements were also carried out in 31 age-matched normotensive controls.</p><p><strong>Results: </strong>In the study population antihypertensive drug treatment lowered clinic blood pressure to values <140/90 mmHg and significantly (P<0.001) reduced both MSNA and NE. However, during treatment the values of these two adrenergic markers remained significantly greater (+70.8 % and +64.4%, respectively) than those detected in the normotensive subjects.</p><p><strong>Conclusions: </strong>These data provide evidence that antihypertensive drug treatment reduces but not normalizes regional and whole body sympathetic CV drive, likely participating at determining the residual CV risk reported in different studies in treated hypertensives.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"351-356"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between the Use of Solid Fuels in Households and Hypertension in Peru: A Population-Based Analysis.","authors":"Carlos Diaz-Arocutipa, Percy Maravi, Lourdes Vicent","doi":"10.1007/s40292-026-00791-8","DOIUrl":"10.1007/s40292-026-00791-8","url":null,"abstract":"<p><strong>Introduction: </strong>The relationship between household air pollution from solid fuel use and hypertension remains uncertain, especially in low- and middle-income countries.</p><p><strong>Aim: </strong>We aimed to examine the association between use of solid fuels in households and hypertension in a large, nationally representative sample from Peru.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of 137,012 adults using data from the 2020-2024 Demographic and Family Health Survey. Cooking fuel exposure was categorized as no exposure (clean fuels), moderate exposure (solid fuel with chimney), or high exposure (solid fuel without chimney). The primary outcome was hypertension, defined as a mean systolic/diastolic blood pressure ≥140/90 mmHg or self-reported diagnosis. The secondary outcomes were systolic and diastolic blood pressure. Modified Poisson and linear regression were used to estimate adjusted prevalence ratios (aPRs) and beta coefficients with their 95% confidence intervals (CIs), respectively.</p><p><strong>Results: </strong>In the adjusted analysis, high exposure to solid fuel was modestly associated with a higher prevalence of hypertension (aPR 1.08, 95% CI 1.02-1.14) compared with clean fuel use. Moderate exposure showed no significant association (aPR 1.01, 95% CI 0.95-1.08). Stronger associations were observed in women (aPR 1.14, 95% CI 1.05-1.23) and urban residents (aPR 1.14, 95% CI 1.05-1.24). High exposure was also associated with small but significant increases in systolic (β = 0.65, 95% CI 0.20 to 1.1 mmHg) and diastolic (β = 0.54, 95% CI 0.26 to 0.81 mmHg) blood pressure.</p><p><strong>Conclusion: </strong>High-intensity exposure to solid cooking fuels, particularly without adequate ventilation, was modestly associated with hypertension and small increases in systolic/diastolic blood pressure. These findings emphasize the importance of ensuring access to clean energy and enhancing kitchen ventilation, particularly among women and urban populations.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"327-335"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Avenue for the Long-Term Upstream Inhibition of the Renin-Angiotensin-Aldosterone System by Inhibiting Angiotensinogen RNA.","authors":"Giovanna Gallo, Giuliano Tocci, Marta Ricci, Maurizio Volterrani, Speranza Rubattu, Massimo Volpe","doi":"10.1007/s40292-025-00759-0","DOIUrl":"10.1007/s40292-025-00759-0","url":null,"abstract":"<p><p>The renin-angiotensin system (RAS) plays a pivotal role in the pathophysiology of several conditions such as hypertension, heart failure and chronic kidney disease. In the last fifty years different therapeutic strategies, including angiotensin converting enzyme inhibitors (ACEi), type 1 angiotensin II receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNi), have been developed to counteract this neurohormonal dysregulation. However, all these therapeutic strategies have a relatively short-term action and they need to be administered orally once or more times every day to achieve the therapeutic purposes with a risk of poor therapeutic adherence.More recently, the search for a new effective strategy to provide a long-term control of hypertension was recently boosted by the availability of novel technologies, such as the angiotensinogen suppression in the liver realized through the silencing of RNA with zilebesiran, a small interfering RNA (siRNA) agent.The purpose of this article is to review the available data on Zilebesiran and to discuss in detail potential advantages in the clinical use as well as the still unresolved potential risks.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"249-255"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials.","authors":"Claudio Borghi, Federica Piani, Athanasios L Manolis","doi":"10.1007/s40292-026-00796-3","DOIUrl":"10.1007/s40292-026-00796-3","url":null,"abstract":"","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"357"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Projections in Hypertension-Related Mortality in the United States: A 1979-2050 CDC WONDER Analysis.","authors":"Muhammad Ahmed, Faizan Abbas, Saifullah Khan, Shaheer Qureshi, Ghulam Taha Khan, Shaheer Bin Shafiq, Wardah Imran, Saad Ahmed Waqas, Marat Fudim, Gregg C Fonarow, Stephen J Greene, Muhammad Shahzeb Khan","doi":"10.1007/s40292-025-00775-0","DOIUrl":"10.1007/s40292-025-00775-0","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality in the United States. Despite advances in detection and treatment, the burden of hypertension-related deaths continues to challenge public health systems. Understanding long-term mortality trends and projecting future patterns is essential to guide policy, allocate resources, and inform prevention strategies.</p><p><strong>Aim: </strong>This study aimed to examine national trends in hypertension-related mortality in the U.S. from 1979 to 2023 using CDC WONDER data and to project mortality patterns through 2050 to support public health planning and intervention efforts.</p><p><strong>Methods: </strong>We extracted age-adjusted mortality rates (AAMRs) per 100,000 population for hypertension as the underlying cause of death from the CDC WONDER database. Temporal trends were assessed using Joinpoint regression to identify significant changes in trajectory, calculating the annual percent change (APC) for specific periods and the average APC for broader trends. Future mortality rates were projected through 2050 using time series models trained on 1979-2015 data, validated against data through 2023, and refined using rolling forecasting techniques.</p><p><strong>Results: </strong>From 1979 to 2023, 2,575,968 hypertension-related deaths occurred. AMRs rose from 27.0 (95% CI, 26.7-27.3) to 40.2 (95% CI, 40.0-40.5), peaking in 2020. Males had consistently higher AAMRs than females. In 2023, AAMRs were 46.7 in males and 33.9 in females. Racial disparities persisted, with Black individuals having a higher AAMR than Whites in 2023 (70.2 vs 35.5). The South remained the most affected region, with Oklahoma (164.1), Mississippi (101.7), and Tennessee (86.0) showing the highest AAMRs in 2023. Forecasts indicate rising hypertension-related mortality, with male AAMR reaching 88.8, Black AAMR 68.4, and older adult AAMR 267.5 by 2050.</p><p><strong>Conclusion: </strong>Hypertension mortality will remain a major public health issue, with growing sex disparities and high rates in older adults and the South, underscoring the need for targeted, long-term interventions.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"287-296"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials.","authors":"Claudio Borghi, Federica Piani, Athanasios L Manolis","doi":"10.1007/s40292-025-00777-y","DOIUrl":"10.1007/s40292-025-00777-y","url":null,"abstract":"<p><p>Hyperuricemia is a metabolic disorder associated with an increased risk of gout, chronic kidney disease (CKD), and cardiovascular disease (CVD). The management of hyperuricemia in conditions where urate deposition has already occurred primarily relies on xanthine oxidase inhibitors (XOIs), such as allopurinol and Febuxostat. Febuxostat, a non-purine selective XOI, has demonstrated superior urate-lowering efficacy, particularly in patients with renal impairment. This review provides an in-depth analysis of Febuxostat's pharmacological properties, clinical efficacy, and safety profile, with a focus on cardiovascular and nephroprotective effects.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"269-276"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}